



PHARMACY RESIDENT RESEARCH

Application Instructions and Guidelines

PROGRAM TIMELINE AT-A-GLANCE:

Application Open: July 1st, 2026

Deadline: September 14th, 2026

Grantees Announced: January 2027

Funding Available: Up to seven (7) grants of \$5,000 each

**Administered by the ASHP Foundation
Funded by donations to the Joseph A. Oddis Endowment**

Grant Program Description

The ASHP Foundation is offering a research grant program to support practice-based research conducted by residents in ASHP-accredited pharmacy residency programs or by residents in pharmacy residency programs that have applied for ASHP accreditation. A secondary goal of the program is to develop pharmacy residents' research skills while fostering development of mentoring relationships with more experienced senior investigators.

The proposed practice-based research must be aligned with the [ASHP Foundation Research Agenda](#).

Submission of studies that evaluate advancing pharmacy practice in hospitals, health systems, and other ambulatory settings is invited. Practice-based research affects a wide range of practice model topics, including the utilization of technology, role delineation changes for pharmacists and non-pharmacists, or enhancing patient care opportunities for pharmacists.

ASHP Foundation

As the philanthropic arm of ASHP, the Foundation shares ASHP's vision that medication use will be optimal, safe, and effective for all people, all of the time. Our mission is to support ASHP by advancing the professional practice of pharmacists and the pharmacy workforce by funding research and education that improves health outcomes through optimal, safe, and effective medication use.

Eligibility

The proposed research must be aligned with the Foundation's [research agenda](#) and be conducted by a pharmacy resident in an ASHP-accredited residency program or a program that has applied for ASHP residency accreditation.

- The principal investigator must be a current pharmacy resident in an ASHP-accredited residency program or a program that has applied for ASHP residency accreditation in the United States.
- The principal investigator must be a licensed pharmacist.
- A senior investigator must participate on the research team as a mentor/advisor.
 - In the application process and grant progress reports, evidence must be included regarding the support and involvement of the senior investigator.
 - For this grant program, the senior investigator assumes responsibility for compliance with all requirements of the grant program.
 - The senior investigator is not required to be a pharmacist.
 - Applicants are strongly encouraged to include an individual with a strong research track record as the senior investigator. History of publication of original research in peer-reviewed biomedical journals and receipt of extramural grant funding will be used to evaluate the senior investigator's research track record.
 - Senior investigators may serve in this role for only one grantee at a time.
- The study timeline should not exceed 18 months from project initiation.
- Applicants should consider allocating a portion of the budget to support biostatistics consultation.

- The proposed research must be submitted to an institutional review board (IRB) for approval. Evidence of IRB approval must be provided to the ASHP Foundation upon acceptance of the grant award.
- The proposed research must comply with their organization's policies and guidelines related to research, such as protection of human subjects and privacy.
- Individuals who previously served as a principal investigator on any ASHP Foundation grant are eligible to apply if all work, including journal submission of the study findings, on the previously funded research is complete. If a tie score occurs during the grant review process, the grant will be awarded to the applicant(s) who has/have not received a grant from the ASHP Foundation previously.
- Not-for-profit organizations, for-profit entities, and government agencies are eligible to apply to this program. If a for-profit entity or government agency is a grant recipient, the monetary award provided by the ASHP Foundation must be received and managed by a 501(c)3 not-for-profit organization. Applicant organizations must be in the United States of America to be eligible for the grant.

Not Eligible to apply OR serve on your research team including as a senior investigator:

- Current members of the ASHP and ASHP Foundation board of directors and board elect
- ASHP and ASHP Foundation staff

Funding Information

Grants will be awarded to pharmacy residents to provide funding for specific practice-based research related to advancing pharmacy practice models and are not intended for long-term support of research programs. Grants will be disbursed directly to the sponsoring institution for administration.

Funds may not be applied to:

- Resident salaries and/or benefits
- Ongoing general operating expenses and/or existing deficits
- Purchase of permanent equipment, facilities, or software, or other capital costs
- Endowment contributions
- Stipends or loans

Funding is generally available for:

- Salary support for study personnel including biostatisticians
- Institutional review board fees
- Consumable supplies and services
- Travel essential to the conduct of the proposed project
- Patient expenses/reimbursement
- Travel to present project findings up to \$1,500 per project. Travel exceeding this range may be submitted for approval following completion of study to over additional presentation opportunities that enhance dissemination of results
- Facilities and administrative cost rates that do not exceed 8% of the total direct costs.

Grant Recipient Responsibilities

- The grant period of activity will begin upon notice of grant award by the ASHP Foundation and will expire 18 months after the initial notification.
- Following initial disbursement of funds, the grantees must submit **Research Progress Reports** every six (6) months via a survey to the ASHP Foundation, until project completion, addressing the following:
 - Progress toward completion of activities included on the study timeline for the period in question.
 - Any protocol modifications and documentation of IRB review and approval of such modifications.
 - A summary of all adverse events associated with execution of the study during the quarter in question and documentation of IRB review of such adverse events.
- **Within 60 days of study completion**, the grantees must submit a **Final Research Report** to the ASHP Foundation. This report will be submitted via a survey and must include:
 - A summary of the study results including statistical analysis, if applicable
 - Preliminary conclusions
 - A summary of all adverse events associated with execution of the study and documentation of IRB review of such adverse events
 - A summary of all protocol modifications and documentation of IRB review and approval of such modifications
 - Lessons learned, including barriers and facilitators
 - Implementation recommendations; and
 - Specific plans for presentation and publication of the study findings.
- Within **60 days of submission** of the Final Research Report, the grantee or grant officer must submit an official **Final Financial Report**. This report must include a complete and full accounting of the expenditure of ASHP Foundation funds related to the execution of the study.
- Any unused funds must be returned to the ASHP Foundation by the grantees within **120 days** of submission of the Final Financial Report.
- If, for any reason, the grantees do not complete the project, the senior investigator must inform the ASHP Foundation in writing within **30 days of study termination**. Within **60 days of study termination**, the grantees are required to complete the Final Research Report and an official Final Financial Report and return any unused funds to the ASHP Foundation as described above.
- The grantee may request one grant extension. Only one extension will be granted for any study. The project must be completed and all other requirements of the grant fulfilled by the end of the extension period.
- If the findings of the above-named study are presented at a national pharmacy meeting, ASHP retains the right of first refusal for presentation of the study and its findings at an ASHP meeting.
- The ASHP Foundation requires submission of study results to a peer-reviewed scientific journal within **6 months** of study completion. If the study results are submitted to a pharmacy journal, the *American Journal of Health-System Pharmacy* retains the right of first refusal for publication.

- The principal investigator will notify the ASHP Foundation when articles containing the study findings are published.
- All presentations, publications, and other communications regarding this study must include the following acknowledgement: “This study was funded (or partially funded) by a research grant from the ASHP Foundation.”
- By accepting this award, the grantee agrees to undertake all reasonable efforts to complete the study and take responsibility for fulfilling the terms described within the award letter.
- The recipient institution is responsible for the actions of its employees and other research collaborators, including third parties, involved in the proposed research. The recipient institution will inquire into and, if necessary, investigate and resolve promptly and fairly all instances of alleged or apparent research misconduct related to this ASHP Foundation-sponsored research in accordance with federal regulations on research misconduct (see 42 CFR part 93, “Public Health Service Policies on Research Misconduct.”) and the U.S. Department of Health and Human Services Grants Policy Statement (see <http://www.ahrq.gov/fund/hhspolicy.htm>).
- The recipient institution must report promptly to the ASHP Foundation any incident of alleged or apparent research misconduct involving ASHP Foundation-sponsored research that it judges as warranting investigation and must advise the ASHP Foundation of any decision to initiate an investigation. The recipient institution must also notify the ASHP Foundation if it intends to close a case at the inquiry or investigation stage based on an admission of responsibility, settlement, or for any other reason.
- If a misconduct investigation has been initiated, the recipient institution must take any necessary steps, in addition to its normal and ongoing responsibilities under the grant, to protect human subjects, protect the scientific integrity of the project, provide reports to the ASHP Foundation, and ensure the proper expenditure of funds and continuation of the project during the investigation, if appropriate.
- If the recipient finds research misconduct by anyone working on ASHP Foundation - supported research, whether at its organization or at a third-party organization, the recipient institution must assess the effect of that finding on the ability to continue that project, as originally approved, and must promptly request ASHP Foundation prior approval of any intended change of PI or other key personnel. In addition, the ASHP Foundation may withdraw approval of the principal investigator or other key personnel, disallow costs associated with the invalid or unreliable research, suspend or terminate, in whole or in part, the grant award.

Grant Selection Criteria

Grant application reviewers will use the following criteria to evaluate applications.

Note: Grant may not be awarded based on external review process

Table 1: Criteria Based Scoring	
Abstract <i>0 points</i>	- Limit to one page with a focus on objectives and methods

Short Essay <i>0 points</i>	Guidance: Essay responses will <u>not</u> be scored separately rather it will be included in reviewer’s assessment of significance. 1. Briefly describe how your research project will highlight the pharmacy workforce’s value to patients, communities and/or organizations
Specific Aims and Hypothesis <i>20 points max</i>	<ul style="list-style-type: none"> - Study aims consistent with the specific grant program focus - Research question(s) is clear and well-defined - Objectives and outcomes are measurable and meaningful - The number of objectives is reasonable based on available funding
Rationale and Significance <i>10 points max</i>	<ul style="list-style-type: none"> - Investigators clearly explain why this study should be undertaken - Study addresses an important problem - Adequate review of the relevant literature is included in the proposal - Investigators identify gaps in the existing evidence base and propose how the proposed study will fill those gaps - Investigators express how scientific knowledge or clinical practice will be advanced - Investigators identify the next logical stages of research beyond the current application
Innovation <i>10 points max</i>	<ul style="list-style-type: none"> - Justification of the proposed study is provided - Challenges existing paradigms or address an innovative hypothesis or critical barrier to progress in the field - Develops or employs novel concepts, approaches or methodologies, tools, or technologies for this area - Outcomes of the study will advance concepts, methods, technologies, treatments, services, or preventative interventions
Investigators and Environment <i>15 points max</i>	<ul style="list-style-type: none"> - Principal investigator (PI), Mentor and other key personnel are appropriately trained and well suited to carry out this work - Proposed research is appropriate to the experience level of the PI and the other members of the research team - PI and research team bring complementary and integrated expertise - The research team is interdisciplinary in its composition - A biostatistician included on the research team - There is evidence of a commitment to collaboration within the research team - Proposal demonstrates that the environment in which the work will be done contributes to the probability of success including evidence of institutional support - There is evidence of institutional support
Approach <i>40 points max</i>	<ul style="list-style-type: none"> - Conceptual or clinical framework, design, methods, and analyses are adequately developed, well-integrated, well-reasoned, and appropriate to the aims of the project - Study methods and procedures are described and include, when applicable: appropriate study design; sampling techniques and a description of the population from which the sample will be recruited; controls; procedures for collection, storage and quality control of data for the major outcome variable, secondary outcomes, and other covariates; assurance of availability of subjects and/or facilities to be used; feasibility of plans for recruitment and retention of subjects; and plans for data analysis including biostatistics support - Study methods enable the researcher to address the stated objectives and hypothesis - Challenges related to the methods are anticipated and alternative approaches are

	proposed - The proposed study methods can be replicated and generalized
Scope and Timeline <i>5 points max</i>	- Evidence is included that the study can be completed in the proposed time period, such as pilot data and/or baseline data demonstrating sufficient patients/subjects - Investigators justify that the proposed timeline is realistic - Sufficient patients/subjects will be available for completion of the project within the proposed time period
Total Criteria Base Score = __ (0-100)	

Additional Review Considerations

Reviewers will consider protection of human subjects, patient privacy and safety protections, and budget/budget justification.

- **Protection of Human Subjects from Research Risk:** Do the investigators adequately address human subjects' protections?
- **Privacy and Security Protections for Patients:** Do the investigators adequately address patient privacy and safety issues?
- **Budget/Budget Justification:** Is the budget and budget justification appropriate for the project?

Overall Funding Priority Score = 1-9

Using the following rating scale, reviewers will provide an overall priority score to reflect their overall assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved. This score represents the reviewer's overall assessment of the application and is not based only on the criteria-based score described below.

Impact	Score	Descriptor	Additional Guidance on Strengths/Weaknesses
High	1	Exceptional	Exceptionally strong with no weaknesses
	2	Outstanding	Outstanding
	3	Excellent	Very strong with only some minor weaknesses
Medium	4	Very Good	Strong but with numerous minor weaknesses
	5	Good	Strong but with at least one moderate weakness
	6	Satisfactory	Some strengths but also some moderate weaknesses
Low	7	Fair	Some strengths but with at least one major weakness
	8	Marginal	A few strengths and a few major weaknesses
	9	Poor	Very few strengths and numerous major weaknesses

Minor Weakness: An easily addressable weakness that does not substantially lessen impact.
Moderate Weakness: A weakness that lessens impact.
Major Weakness: A weakness that severely limits impact.

Itemized Instructions for Online Grant Application

Project

- Study Title: The study must relate directly to advancing pharmacy practice models in hospitals, health systems, or other ambulatory settings.
- Project Period: Funds may be requested for a maximum period of 18 months.
- Total Budget Requested: Total amount requested cannot exceed \$5,000 for an 18-month period. The **total budget**, inclusive of direct costs and facilities/administrative costs, cannot exceed \$5,000.
- Is the study aligned with the ASHP Foundation Research Agenda?

Pharmacy Resident Investigator

Note: The pharmacy resident must be participating in an ASHP- accredited residency program or a program that has applied for ASHP accreditation in the U.S.

- Resident Investigator Name
- ASHP Member ID (if known, active membership-only)
- Credentials (Degrees(s))
- Current Position Title & Department
(e.g., PGY1 Pharmacy Resident or PGY2 Pharmacy Resident, Oncology]
- Organization Name
- Institution Mailing Address
- Business phone number
- Cell phone number (optional)
- Business email address
- Personal email address
Email address that is most commonly used for frequent communication (for post-grant use)
- Percentage Effort Committed to Study:
Percent effort is the total percentage of the investigator's time that he/she will commit to this study. For example, if an investigator works 50 hours per week and expects to commit 5 hours per week to the study, their percent effort would be 10%.
- Affirm that the principal investigator is a PGY1 or PGY2 pharmacy resident.

Senior Investigator

Note: The senior investigator does not have to be a pharmacist. However, they must have the requisite research skills and experience to supervise the resident's research activities. Applicants are strongly encouraged to identify individuals with a history of publishing original research in peer-reviewed biomedical journals and receipt of extramural grant support as the senior investigator. The individual named as senior investigator must assume primary responsibility for the study and serve as the senior investigator for the entire grant period. *Members of the ASHP and ASHP Foundation Board of Directors, as well as ASHP and ASHP Foundation staff are not eligible to serve as a member of the investigator team for this research grant program.*

- Senior Investigator Name

- ASHP Member ID, if applicable
- Degree(s)
- Current Position Title
- Institution/Organization Name
- Institution Mailing Address
- Business Phone Number
- Cell Phone Number
- Email Address, most used for frequent communication
- Percentage Effort Committed to Study:
Percent effort is the total percentage of the investigator's time that he/she will commit to this study. For example, if an investigator works 50 hours per week and expects to commit 5 hours per week to the study, his/her percent effort would be 10%.

Sponsoring Institution and Grant Officer

Note: Not-for-profit organizations, for-profit entities, and government agencies in the U.S. are eligible to apply to this program. If a for-profit entity or government agency is a grant recipient, the monetary award provided by the ASHP Foundation must be received and managed by a 501(c)3 not-for-profit organization and this is the information that should be provided in this section. *Grant checks will be made payable to the institution name listed.*

- Is the institution/organization a tax-exempt entity?
- Sponsoring Institution/Organization Name
- Grant Officer Name - List the grant officer at the sponsoring institution who will be responsible for monitoring grant fund use. For institutions that do not have internal grants management divisions, the institution must identify an appropriate entity (e.g., related healthcare foundation) to receive the funds and monitor their use.
- Grant Officer Title - Title of the grant officer must directly reflect an appropriate individual to receive the funds and monitor their use.
- Business Telephone Number
- Business Email Address

Other Investigators

All other professionals engaged in the project for whom salary support is NOT being requested must be named in this section with their credentials, institution name and department/division, email address, and their percent effort dedicated to this study. If organizational in-kind contribution of time for these members of the investigator team will be required for completion of the proposed research, a support letter that confirms this institutional support should be included.

(Do not include the pharmacy resident or senior investigators in this section.)

- Provide: Full Name, Title & Credentials, Institution Name, Dept./Division, Email Address, and Percent Effort.

Detailed Budget

(a) PERSONNEL

All personnel for whom salary support are requested must be named in this section. Salary support is available only for study personnel (e.g., technical personnel; clerical personnel; and

other professional personnel.) Resident salaries and fringe benefits are not allowed under this grant program. Strong consideration should be given to allocating a portion of the budget to support biostatistics consultation. In the personnel budget justification section, provide a detailed justification that describes each individual's role. The budget justification should correspond directly to the project plan.

(b) CONSUMABLE SUPPLIES

All consumable supplies must be itemized as to description, number, cost per unit, and total cost. If exact costs are not known, estimates must be provided. Provide detailed justification for each budget item. The budget justification should correspond directly to the project plan.

(c) TRAVEL

Only travel costs essential to the conduct of the project are eligible for funding. Travel to present project findings is acceptable up to \$1,500 per project. In the travel budget justification, provide a detailed justification for each budget item. All travel to present study findings should be supported through grant or institutional funds. Estimated costs for meeting registration fees, airfare, lodging, meals, and ground transportation must be provided.

(d) OTHER EXPENSES

All other expenses not already specified must be itemized and justified in relation to the project. Permanent equipment, facility construction or renovation, and software are not eligible for funding. Provide detailed justification for each budget item. The budget justification should correspond directly to the project plan.

(e) IN-KIND SERVICES

Provide any detail necessary to describe the extent of the in-kind services provided

(f) FACILITIES AND ADMINISTRATIVE COSTS

Requests for support for facilities and administrative cost rates **cannot exceed 8% of the direct costs.**

Research Type & Topic

What type of research do you intend to conduct?

- Case-control
- Cohort (e.g., retrospective or prospective in which cohorts of patients are followed through time until development of outcome)
- Descriptive (e.g., case report, series, etc.)
- Experimental (e.g., randomized controlled trial)
- Survey
- Performance Improvement (e.g. medication-use evaluation)
- Systematic review or meta-analysis
- Other – text entry

Which topic(s) is the primary focus of your project?

- | | |
|--|---|
| <input type="radio"/> Access to care | <input type="radio"/> Biosimilars |
| <input type="radio"/> Antibiotic stewardship | <input type="radio"/> Cardiology |
| <input type="radio"/> Anticoagulant | <input type="radio"/> Compounding |
| <input type="radio"/> Automation/technology | <input type="radio"/> Continuum of care |

- Critical Care
- Diabetes
- Disaster planning and prevention
- Drug affordability
- Drug diversion
- Drug shortages
- Education and training
- Electronic health records
- Emergency medicine
- Formulary management
- Gastroenterology
- Geriatrics
- Health services
- Hematology
- Infectious diseases
- Medication adherence
- Medication reconciliation
- Medication safety
- Nephrology
- Neurology
- Nutrition
- Oncology
- Opioid
- Pediatrics
- Pharmacogenomics
- Pharmacy technicians
- Primary care
- Psychiatry
- Pulmonology
- Smoking cessation
- Solid organ transplant
- Specialty pharmacy
- Substance use disorder
- Telemedicine
- Vaccines
- Weight loss
- Well-being
- Women's health
- Workforce

Application Essay Prompt

Briefly describe how your research project will highlight the pharmacy workforce's value to patients, communities and/or organizations (approx. 250 words). *This will not be scored separately, rather it will be included in reviewers' assessment of significance.*

Additional Application Documents Required – UPLOADS (4)

1. ABSTRACT OF PROPOSAL

May not exceed one (1) page (using 11-point font or larger, 8.5 x 11-inch paper, 1-inch margins, single spacing and single sided pages). Applicants should strictly comply with font size, paper size, spacing and page limit requirements.

2. RESEARCH PLAN

Description of proposed research plan on no more than ten (10) pages (using 11-point font or larger, 8.5 x 11 inches paper, 1-inch margins, single spacing and single-sided pages) with numbered pages under the following headings:

- Specific Aims and Hypothesis
- Rationale and Significance
- Innovation
- Investigators and Environment
- Approach
 - Detailed study procedures;
 - Power calculation, if applicable;
 - Plans for data analysis; and
 - Procedures for recruitment, retention, and protection of subjects, if applicable
- Human Subjects/Privacy
- Scope and Timeline
- References

3. BIOGRAPHICAL DATA

Provide biographical sketches for both resident and senior investigators in a one (1) combined PDF document. The biographical sketch should list all of the applicants' peer reviewed publications and should be submitted in the format included below. A downloadable template can also be found on within the online application. *Note: CVs will not be accepted.*

BIOGRAPHICAL SKETCH				
Provide the following information for the Senior/key personnel and other significant contributors. Follow this format for each person. DO NOT EXCEED FIVE PAGES.				
NAME:				
eRA COMMONS USERNAME (credential, e.g., agency login):				
POSITION TITLE:				
EDUCATION/TRAINING (<i>Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.</i>)				
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Start Date MM/YYYY	Completion Date MM/YYYY	FIELD OF STUDY
<p>A. Personal Statement</p> <p>B. Positions, Scientific Appointments and Honors</p> <p>C. Contributions to Science</p>				

4. CERTIFICATION AND ACCEPTANCE

This "certification" must be signed by the pharmacy resident investigator, the senior investigator, resident program director or director of pharmacy, and the grant officer.